Related Experiment Video

Updated: Jul 11, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies

Victoria A Joshi1, Raju Kucherlapati

  • 1Harvard Medical School-Partners Healthcare Center for Genetics and Genomics, Department of Pathology, Massachusetts General Hospital, MA, USA. vjoshi@partners.org

Pharmacogenomics
|October 11, 2007
PubMed

Insights

Second-generation epidermal growth factor receptor (EGFR) therapies show promise in overcoming resistance to first-generation treatments for non-small-cell lung cancer. Understanding resistance mechanisms aids patient selection for improved targeted therapy outcomes.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR)-targeted therapies have shown variable efficacy in non-small-cell lung cancer (NSCLC).
  • Molecular mechanisms underlying response and resistance are crucial for optimizing treatment strategies.
  • Patient selection based on predictive biomarkers can improve therapeutic outcomes.

Purpose of the Study:

  • To review the clinical evaluation of second-generation EGFR-targeted therapies.
  • To discuss the role of understanding molecular mechanisms in overcoming resistance to EGFR inhibitors.
  • To highlight the application of predictive pharmacogenomics in targeted cancer therapy.

Main Methods:

  • Review of clinical trial data for second-generation EGFR inhibitors.
  • Analysis of molecular mechanisms of resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs).
  • Discussion of pharmacogenomic principles in patient stratification.

Main Results:

  • Second-generation EGFR therapies are under clinical evaluation for their potential to circumvent resistance.
  • Understanding resistance mechanisms informs the development of more effective targeted treatments.
  • Predictive pharmacogenomics is key to personalized medicine in NSCLC.

Conclusions:

  • Second-generation EGFR inhibitors may overcome certain resistance mechanisms to first-generation TKIs.
  • Continued research into molecular mechanisms is vital for advancing targeted cancer therapy.
  • Pharmacogenomic approaches are essential for improving patient selection and treatment efficacy in NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...